Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,144 JPY | -0.02% | -2.94% | -14.12% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.78 for the current period. Therefore, the company is undervalued.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.12% | 5.71B | C+ | ||
-39.33% | 13.67B | B- | ||
-8.96% | 7.95B | B | ||
+4.90% | 5.86B | C | ||
-2.77% | 4.6B | D- | ||
+70.58% | 4.5B | C | ||
-8.29% | 3.77B | B | ||
-22.05% | 3.05B | C- | ||
-12.77% | 2.81B | C- | ||
-12.69% | 2.57B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3088 Stock
- Ratings MatsukiyoCocokara & Co.